MKA
DMTK

M. Kulyk & Associates’s DermTech, Inc. Common Stock DMTK Stock Holding History

M. Kulyk & Associates’s Portfolio DMTK Stock Details DMTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-9,073
Closed -$461K – 74
2021
Q1 		$461K Buy
+9,073
New +$475K 0.17% 54

Other funds holding DMTK

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ICM
ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

M. Kulyk & Associates's DMTK Position: Q2 2021 in Review

M. Kulyk & Associates sold out of DermTech, Inc. Common Stock (DMTK) in Q2 2021, closing a stake of 9,073 shares — an estimated $461K sold.

M. Kulyk & Associates first reported a position in DMTK in Q1 2021 and held it in 1 quarter. The position peaked at $461K in Q1 2021. 176 funds tracked by Wall St. Rank hold DMTK as of Q2 2021.

  • M. Kulyk & Associates reported no remaining DermTech, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • M. Kulyk & Associates sold 9,073 DermTech, Inc. Common Stock shares in Q2 2021, an estimated $461K.
  • M. Kulyk & Associates first reported a position in DermTech, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • M. Kulyk & Associates's DermTech, Inc. Common Stock position peaked at $461K in Q1 2021.
  • 176 funds tracked by Wall St. Rank held DermTech, Inc. Common Stock as of Q2 2021.

Based on M. Kulyk & Associates's 13F filing for Q2 2021, filed 21 Jul 2021.